Abstract
Chronic hepatitis C, without treatment, can cause liver cirrhosis, liver failure and liver cancer. The availability of new oral direct acting antivirals, such as the protease inhibitors simeprevir, asunaprevir and paritaprevir, the NS5A inhibitors daclatasvir, ledipasvir, and ombitasvir, the polymerase inhibitors Sofosbuvir and dasabuvir have resulted an enormous progress in the treatment of chronic hepatitis C, leading to >90% sustained viral response rates. Even the hard-to-treat or previously treatment ineligible patients can be cured with the combination of these drugs. Furthermore the treatment duration is much shorter, and the side effects are minimal. Today, treatment of all hepatitis C virus infected patients is recommended, and the best choices are the interferon-free options. Eradication of hepatitis C virus has become realistic, however, appropriate screening programs are mandatory to achieve this goal.
Keywords:
antiviral treatment; antivirális kezelés; chronic hepatitis C; direct acting antivirals; direkt ható antivirális szerek; krónikus C hepatitis.
MeSH terms
-
2-Naphthylamine
-
Administration, Oral
-
Anilides / administration & dosage
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use*
-
Benzimidazoles / administration & dosage
-
Carbamates / administration & dosage
-
Clinical Trials as Topic
-
Cyclopropanes
-
Drug Therapy, Combination
-
Fluorenes / administration & dosage
-
Hepacivirus / drug effects*
-
Hepacivirus / physiology
-
Hepatitis C, Chronic / drug therapy*
-
Heterocyclic Compounds, 3-Ring / administration & dosage
-
Humans
-
Imidazoles / administration & dosage
-
Interferons / administration & dosage
-
Interferons / adverse effects
-
Isoquinolines / administration & dosage
-
Lactams, Macrocyclic
-
Liver Neoplasms / prevention & control
-
Liver Neoplasms / virology
-
Macrocyclic Compounds / administration & dosage
-
Nucleic Acid Synthesis Inhibitors / therapeutic use*
-
Proline / analogs & derivatives
-
Protease Inhibitors / pharmacology
-
Protease Inhibitors / therapeutic use*
-
Pyrrolidines
-
Simeprevir
-
Sofosbuvir
-
Sulfonamides / administration & dosage
-
Uracil / administration & dosage
-
Uracil / analogs & derivatives
-
Uridine Monophosphate / administration & dosage
-
Uridine Monophosphate / analogs & derivatives
-
Valine / analogs & derivatives
-
Viral Load / drug effects
-
Viral Nonstructural Proteins / antagonists & inhibitors*
-
Virus Replication / drug effects*
Substances
-
Anilides
-
Antiviral Agents
-
Benzimidazoles
-
Carbamates
-
Cyclopropanes
-
Fluorenes
-
Heterocyclic Compounds, 3-Ring
-
Imidazoles
-
Isoquinolines
-
Lactams, Macrocyclic
-
Macrocyclic Compounds
-
NS3 protein, hepatitis C virus
-
NS4 protein, hepatitis C virus
-
Nucleic Acid Synthesis Inhibitors
-
Protease Inhibitors
-
Pyrrolidines
-
Sulfonamides
-
Viral Nonstructural Proteins
-
ledipasvir
-
ombitasvir
-
Uracil
-
Interferons
-
Proline
-
Simeprevir
-
2-Naphthylamine
-
dasabuvir
-
Uridine Monophosphate
-
NS-5 protein, hepatitis C virus
-
Valine
-
daclatasvir
-
paritaprevir
-
asunaprevir
-
Sofosbuvir